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Abstract 
 A genetic interruption of Bacillus subtilis 168's native nitric oxide synthase enzyme (bsNOS) is to 
be created by inserting a gene for kanamycin resistance (KAN) into the center of the gene. To accomplish 
this, a plasmid has been constructed (pUC19∆bsNOS) which includes the bsNOS gene separated into 5' 
and 3' halves with a KAN gene from p34S between them. The plasmid vector was isolated by digesting 
Escheria coli plasmid pUC19 with KpnI and PstI, and the KAN gene was cut from Escheria coli plasmid 
p34S using XbaI. The 5' and 3' halves of the bsNOS gene were amplified using the polymerase chain 
reaction with custom primers that imparted appropriate digestion sites to the ends of both amplified 
fragments. The vector and bsNOS fragments were all produced and ligated into a preliminary plasmid 
form (pNOS20) and amplified. This plasmid was subsequently digested with XbaI, and the KAN 
fragment was ligated into place between the 5' and 3' XbaI sites. Knockout colonies were generated by 
amplifying the desired insert from the pUC19∆bsNOS plasmid using PCR and then using it for 
transforming competent wild-type Bacillus subtilis via electroporation. Potential Bacillus subtilis 
∆bsNOS knockout colonies may have been generated but are pending confirmation. 
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Chapter 1: Background 
Nitric Oxide as a Biological Signal 
 Nitric oxide (NO) was first identified as a eukaryotic trans-cellular signaling molecule in 1987 (1) 
and was later shown to be generated from L-arginine by an enzyme (Figure 1.1-A) known as nitric oxide 
synthase (NOS) (2). Mammalian NOS enzymes have been found to perform functions ranging from 
vasodilatation (3) to acting as a broad-spectrum antimicrobial during immune system responses (4). 
 Nitric oxide is effective as a broad spectrum antibiotic because of its high reactivity as a free 
radical species and its lipophilic nature (5). It is a small, membrane-permeable molecule capable of 
competitively binding precious metals, inhibiting enzymes, and generating oxidizing chemicals such as 
nitric acid, peroxynitrite, or superoxide in solution which in turn damage DNA (5). In eukaryotes, nitric 
oxide is generally produced at concentrations high enough to have these effects by inducible NOS (iNOS) 
during macrophage attack. However, nitric oxide has also been shown to affect bacteria at concentrations 
too low for toxic or acidifying effects (6), indicating more involved mechanisms at work. 
 Later efforts revealed prokaryotic NO-dependent pathways associated with denitrification and 
anaerobic gene expression. Nitric oxide was shown to be an activator of transcription factors ResD and 
ResE, key signals for anaerobic gene expression in Bacillus subtilis (Figure 1.1-B) and other microbes. 
While they were known at the time to be activated under low-oxygen conditions, it was discovered that 
full activation also required elevated concentrations of NO (7-9). This mechanism suggested that many 
bacteria have evolved to detect NO as an indication of impending oxidative stressors, such as those 
typically experienced during immune system attack. In non-infectious microbes such as Bacillus subtilis, 
NO likely warns of increasing concentrations of nitrosative species produced by soil denitrifiers sharing 
the microbe's environment. Nitric oxide would have been a likely candidate during the evolution of such a 
signal as its permittivity to cell membranes makes it one of the earliest species' detectable (10). 
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Nitric Oxide Synthase in Bacillus subtilis 
 It is perhaps because of NO's common roles as an antimicrobial and exogenous signal molecule 
that the discovery of nitric oxide synthase analogs in the prokaryotic species Bacillus subtilis was 
considered surprising. In 2002 the completion of the Bacillus subtilis genome sequencing project made it 
possible to perform Basic Local Alignment Search Tool (BLAST) searches on the bacterium's genome 
(11), revealing a sequence homologous to mammalian NOS. The protein encoded by this gene was 
isolated and shown to actively manufacture NO when given concentrations of NADPH, L-arginine, and a 
mammalian reducing domain (12). 
 Attempts to determine the purpose of this NO production began with comparisons of Bacillus 
subtilis' nitric oxide synthase enzyme (bsNOS) (Figure 1.3) and its mammalian analogs (mNOS). 
Mammalian NOS enzymes are homodimeric enzymes 135-160 kDa in size, and have been classified into 
three forms: endothelial (eNOS), neuronal (nNOS), and inducible (iNOS). Inducible NOS produces high 
concentrations of NO during immune system activation, while eNOS and nNOS (collectively known as 
constitutive or cNOS) produce lower concentrations of NO for use as second messengers targeting 
isoforms of soluble guanylyl cyclase. All three classes consist of a single polypeptide with two functional 
domains. The N-terminal domain binds the redox cofactor tetrahydrobiopterin (H4B) and also secures a 
cytochrome P450-like heme group containing the enzyme's reactive iron species (13, 14). The C-terminal 
strand binds reducing species NADPH, and also flavin adenine dinucleotide and flavin mononucleotide 
(FAD and FMN, respectively) which serve to shuttle electrons from NADPH to the iron center. 
Eukaryotic NOS enzymes are dependent upon the Ca2+-sensing protein calmodulin (CaM), which upon 
binding triggers a conformational change in the NOS dimer that facilitates this electron transfer. The 
enzyme has no activity outside of its dimeric form, which is stabilized by a zinc-binding domain located 
on the N-terminal end (13, 14). With regards to activity, mammalian NOS produces NO and citrulline 
from L-arginine in the presence of CaM, H4B, and oxygen (15). One exception is seen in iNOS, which 
has CaM bound permanently and is therefore perpetually active, dependent only on transcription and the 
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presence of substrates. All forms of NOS have activity modulated by feedback inhibition: increasing 
concentrations of NO result in lower levels of manufacture. 
 The bsNOS gene shares 34% overall sequence similarity with cNOS, and the protein shows 52% 
structural similarity in active site regions (12). It is smaller than eukaryotic NOS by approximately 360 
residues and is missing key components of the cNOS species. The dimer-stabilizing N-terminal hook is 
absent, as is part of the H4B-binding domain (15), and mNOS's internal reductase domain. Consequently, 
bsNOS has been shown to scavenge reductase activity from other reductase enzymes (of which there are 
several in the Bacillus subtilis genome) which are not explicitly dedicated to NO production (16). 
 In 2005, Ivan Gusarov and Evgeny Nudler suggested that native-manufactured nitric oxide 
functioned as a means of "instant adaptation" when a microbe was exposed to oxidative stress. While 
exogenous NO would promote a switch to anaerobic metabolism, significantly lower levels of 
endogenous NO were suggested to perform two additional functions: inhibit the formation of dangerous 
oxidative chemicals, and activate the oxidative stress response enzyme superoxide dismutase A (SodA, 
also known as catalase A or KatA), which actively neutralizes oxidative species. 
 Damage from oxidative chemicals such as hydrogen peroxide is brought about by the Fenton 
reaction (Figure 1.3), a sequence of steps in which the oxidative species reacts with cytoplasmic Fe2+ to 
generate OH., a radical chemical species capable of damaging DNA. However, the already low 
cytoplasmic concentration of Fe2+ is rapidly consumed as this occurs, and OH. production would stop 
completely without reducing activity to return the resulting Fe3+ back to Fe2+. In microbes like Bacillus 
subtilis, this activity is provided by the cytoplasmic concentrations of the amino acid cystine, a thiol 
species. This oxidized form of cysteine, known as cystine, must be reduced as well, and this is 
accomplished by thioredoxin and its counterpart thioredoxin reductase (TrxOX and TrxRED, respectively). 
Left alone, cells exposed to oxidative chemicals oxidize cytoplasmic iron to produce damaging ·OH 
species, at which point cytoplasmic cystine would reduce this iron back to Fe2+ for another reaction. 
Cysteine would then be actively reduced by cellular TrxOX/TrxRED, perpetuating the cycle at the expense 
of cellular energy stores until cell death. Gusarov and Nudler showed that to arrest this cycle, cytoplasmic 
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NO serves to inhibit the activity of thioredoxine reductase, ultimately limiting the availability of reduced 
iron with which to perpetuate the reaction. This system acts as a buffer which can provide several minutes 
of protection which allows a stressed cell to activate a more elaborate transcription-based oxidative stress 
response. One such condition, the activation of SodA, is also NO dependent; the enzyme is S-nitrosylated 
by NO to become active, and in turn begins actively scavenging oxidative species (10). 
 This hypothesis was confirmed four years later, with one addition: NO is also suggested to play a 
key role in antibiotic resistance. Given that the modes of activity of many bactericidal species ultimately 
come down to production of oxidative species, NO's activity in minimizing oxidative damage in general 
may be a subsequent function. It was known that endogenous NO concentrations were generally too low 
to compete with oxidative species stoichiometrically, though it is suggested that they may still have an 
impact on incoming antibiotic species. Gusarov and Nudler indicated that while this was an insufficient 
function on its own, endogenous NO levels did reduce the impact of antibiotic species such as acriflavin 
and pyocyanin early on by directly modifying them in addition to halting the Fenton cycle they are 
designed to initiate. The combination of these two functions with NO's activation of oxidant-scavenging 
SodA makes native NO concentrations an effective means of preempting, detecting, and responding to 
oxidative stress levels in Bacillus subtilis, and may have many analogous defense mechanisms among 
prokaryotic organisms. Other species have already been shown to employ this tool, including 
Staphylococcus aureus and Bacillus anthracis. Indeed, it has been suggested that this mechanism may 
open a new avenue for improving antibiotic effectiveness: by inhibiting bacterial NO synthesis, it is 
possible that antibiotic and/or oxidative attack from both medical treatments and immune responses could 
be bolstered (17), and given the inherent differences between mammalian and prokaryotic NOS enzymes 
it is plausible that such treatments could be applied chemically with minimal effect on the host. 
 However, kinetics studies of bsNOS do not indicate that NO concentrations resulting from the 
enzyme during normal conditions would be sufficient to provide any stoichiometrically relevant level of 
protection against molecules either oxidative or antibiotic. The rate of dissociation of the Fe(III)-NO 
complex (the releasing step for NO) is between 10 and 20 times slower than mNOS, and establishes a 
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limit for how quickly the enzyme can manufacture NO; bsNOS ultimately generates different N-oxides if 
the rate of Fe(III)-NO complex formation significantly exceeds its rate of dissociation (12). Combined 
with NO's particularly short half life in biological solutions, this characteristic makes the possibility of 
bsNOS single-handedly maintaining levels stoichiometrically comparable to sudden oxidative stress 
unlikely, and so much of the direct neutralization behavior observed may be provided by exogenous 
rather than endogenous sources. 
 Given that bsNOS is most comparable in activity to eukaryotic cNOS isoforms, it is possible that 
native NO production in Bacillus subtilis and other prokaryotic species is used for chemical signaling. 
Further, given bsNOS's low output it is likely that the message it is sending is not intended to be 
effectively transmitted during oxidative attack at all as it would be immediately swamped by high levels 
of exogenous NO. However, the typical receptor of eukaryotic NO signals -- guanylyl cyclase -- is not 
present in the Bacillus subtilis genome, indicating that if NO's function is as a second messenger, some 
other receptor(s) must be present (12). 
 
Interest in Bacillus subtilis Nitric Oxide Activity 
 Interest in characterizing this function in Bacillus subtilis originates from the species' status as a 
model bacterium. It is a common non-pathogenic, gram-positive soil bacterium, and has been studied and 
characterized intensely; to date, its genome coding roughly 4100 genes has been mapped (18). Further, it 
is cultured and handled easily, and is of close evolutionary relationship to species such as Staphylococcus 
aureus, a pathogen of interest in recent years after the emergence of multiple-resistant strains (19). It is 
hoped that advances in our understanding of this species can be applied across several cell lines, 
potentially toward the establishment of new treatment options for infection. 
 Previous work used chemical inhibition of bsNOS with aminoguanidine to show that inhibition of 
NO signaling during logarithmic growth (and without significant oxidative stress) resulted in the down-
regulation of an MreB-like protein, a nucleoside diphosphate kinase, and a phage shock protein (20). 
While to date these findings have not pinpointed the nature and function of the pathways involved with 
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NO, they do indicate that some form of signal transduction may be operating outside of oxidative stress 
conditions. Our work attempts to supplement this data by producing a genetic knockout of bsNOS and 
comparing the resulting difference in protein inventories using two-dimensional gel electrophoresis. This 
should confirm that differences observed that are not a direct result of chemical treatment but of the 
absence of a native NO signal. 
 
Intended Study 
To achieve this, a plasmid was designed (arbitrarily designated pUC19∆bsNOS) which contained 
a gene coding kanamycin (KAN) resistance (~1 kbp in length) inserted into the middle of the bsNOS 
coding gene (Figure 1.5). To construct this plasmid, the sequence of bsNOS was selectively amplified in 
two halves (5' and 3') using the polymerase chain reaction (PCR). By designing custom primers it was 
possible to impart digestion sites at both ends of each fragment, allowing them to be selectively cut and 
ligated to desired sequence fragments simply by matching digestion sites during ligation procedures. The 
gene for kanamycin resistance was digested out of the plasmid p34S with xbaI, and the vector species 
used was made from a pUC19 plasmid linearized with kpnI and pstI enzymes. The use of a plasmid made 
possible the amplification of this DNA stock by transforming it into competent DH5α cells via heat shock 
and then growing colonies selected for kanamycin resistance. The desired plasmid was then collected 
using mini-prep. 
The sequence to be inserted (the bsNOS sequence with the inserted KAN domain) was amplified 
out of the pUC19∆bsNOS plasmid using PCR and then inserted into competent wild-type Bacillus subtilis 
cells using electroporation, a method for generating pores in cell membranes via electrical field in order to 
insert otherwise membrane-impermeable molecules (21). Following electroporation, B. sub cells are 
incubated in LB broth and then grown on kanamycin-laced plates in order to select for colonies with 
successfully incorporated inserts. 
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Ideally, cells dividing in the presence of added DNA incorporated the insert by double 
recombination. In the process of replicating genomic DNA, these cells enzymatically separated the two 
DNA strands as well as the added DNA insert, and with its two ends matching the sequence of bsNOS the 
insert was able to match up with its compliment in the genome and allow the formation of a Holliday 
junction. From here, there were two possibilities: either the Holliday junction could twist to allow one 
strand with the insert to recombine with one strand of the wild-type genome (single recombination), or it 
could twist to combine two DNA strands containing the desired insert (double recombination). The latter 
of these two events should have yielded cells with a full interruption of the bsNOS gene (∆bsNOS); 
having both copies of the gene interrupted with the gene for KAN resistance, it would now be impossible 
for the bacterium to manufacture functional bsNOS and, subsequently, NO. This can be confirmed using 
PCR to amplify the entire insert sequence and then observing them in an agarose gel. The presence of 
bands at ~1 kbp and ~2 kbp indicated a single recombination as both a wild type and an insert strand of 
DNA were present, but the presence of a single ~2 kbp strand would have indicated that all present copies 
of the gene had received an insert and had thus undergone double recombination. With a suitable 
knockout colony chosen, it will then be possible to generate 2-dimensional gel electrophoresis images for 
statistical comparison with chemically-inhibited wild-type Bacillus subtilis gels. 
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Figure 1.1. Comparison of Mammalian nNOS and bsNOS. (A) Mammalian neuronal nitric oxide 
synthase (nNOS) in its dimeric form, complexed with N~5~-(2-(methylsulfanyl)ethanimidooyl)-L-
ornithine (22).(PDB code 3JT3) (B) Bacillus subtilis nitric oxide synthase (bsNOS) with heme groups 
bound (PDB code 2FBZ ) (23). 
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Figure 1.2. Electron Micrograph Image of Bacillus subtilis Cells (24). 
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Figure 1.3. Nitric Oxide Interaction with Fenton Reaction, where KatA indicates superoxide 
reductase A (SodA), and Thioredoxin(OX) indicates oxidized thioredoxin, which is inactive until reduced 
by thioredoxin reductase. Green arrows indicate activation pathways,while red indicates inhibition. 
Adapted from Gusarov and Nudler, Figure 5 (10). 
 
 
 
 
 
 
 
 
 
 
11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. pUC19ΔbsNOS Plasmid Map with approximate fragment sizes and relevant restriction 
sites. 
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Chapter 2: Methods 
Cell Cultures 
 Bacillus subtilis cell stocks were frozen for long-term storage at -80 °C, and stock cultures were 
grown by collecting shavings of the frozen pellets with a 1 mL micropipette tip and immersing them in 50 
mL sterile Luria-Bertani (LB) broth. Cultures were grown in loosely capped sterile 250 mL polycarbonate 
Erlenmyer flasks and incubated at 37 °C with vigorous shaking (100-160 rpm) for at least 10 hours prior 
to use. Growth in a single flask was not allowed to proceed for more than 24 hours in order to limit 
stresses from nutrient exhaustion or increasing waste concentrations; prior to this time a 1:100 dilution 
with fresh broth was performed in a new sterile flask. Cultures were not passaged more than four times. 
 Competent Bacillus subtilis cultures were produced for electroporation procedures using fresh, 
750 µL stocks of cells frozen once at -80 °C. Stocks were thawed on wet ice for 10 minutes and diluted 
1:200 in sterile LB broth in a loosely capped conical tube, then incubated overnight with shaking at        
37 °C. The resulting stock broth was then diluted 1:20 in sterile LB then incubated at 37°C with shaking, 
with optical density readings taken every 30 minutes. Once stocks had reached approximately 0.600 
OD(595nm) (~3 hr), they were centrifuged at 4,400 rpm for 2 minutes to pellet and the LB broth was 
decanted using an aspirator. Pellets were washed three times with deionized water (1/3 the volume of the 
decanted broth), then twice more with the same volume of sterile 10% glycerol in deionized water. Pellets 
were then resuspended in sterile 10% glycerol solution (1:40 wash volumes) and diluted with an equal 
volume of deionized water to give a suspension in 5% glycerol. Stock was then divided up into 50 µL 
aliquots and frozen on dry ice, then stored at -80°C until used. 
 Competent Escheria coli DH5α stocks were purchased from Invitrogen (Catalog #18258-012) 
and stored at -80°C. Stocks were thawed, divided into 15µL aliquots, and refrozen on dry ice and stored at 
-80°C. 
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Transformation 
 E. coli DH5α aliquots were removed from -80°C freezer and thawed on ice for 10 minutes, then 
plasmid samples were added to give 25-50 ng/µL plasmid in each solution. Samples were then mixed by 
tapping and incubated on ice for 20 minutes. Next, samples were heat shocked for 1 minute in a 42°C 
water bath and rescued by diluting 1:30 in sterile Super Optimal Broth (S.O.C) (VWR Direct, Catalog # 
101446-764) and incubating 2 hours at 37°C with shaking. 
 Bacillus subtilis 168 aliquots were removed from -80°C storage and thawed on ice for 10 
minutes, and then plasmid samples were added to give 25-50 ng/µL plasmid concentrations in each 
solution. Samples were mixed by tapping and electroporated at settings known to be effective with 
Bacillus subtilis from previous works (25) (25 mF, 200W and 2.5 kV), then rescued in 1:10 dilutions of 
S.O.C broth incubated 4 hours at 37°C with shaking. 
 Rescued stocks were removed from incubation and 50-200 µL of each were used to inoculate 
appropriate antibiotic plates. For lower-yield plasmids (modified pUC19 vectors or ligation samples in 
particular) stocks were then centrifuged at 13,200 rpm for 1 minute to pellet the cells, then 50-80% of 
remaining broth was removed and the pellets were resuspended via pipetting. The resulting concentrated 
suspensions (100-200 µL) were then plated onto appropriate antibiotic plates. 
 
Antibiotic Selection 
 Selection was performed on 1% LB-agar plates containing 50-100 µg/mL kanamycin (KAN), 
ampicillin (AMP), or both. Plates were produced in batches using roughly 25 mL of the broth-agar 
mixture per plate, and prior to use this broth-agar solution was autoclaved at 125°C for 15 minutes (not 
including heating/cooling time). The solution was allowed to cool to ~65°C based on touch, at which 
point appropriate volumes of antibiotics were added and mixed by gentle swirling. Plates were then 
poured by hand and allowed to cool and solidify on the bench top covered at room temperature (~15 min) 
before being stored at 4°C. Plates were used within 1 week of pouring at all times to avoid antibiotic 
degradation. 
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 Cell cultures to be plated were added to the top of solidified plates in volumes of between 100 
and 250 µL and were spread using sterile technique. Plates were then incubated overnight at 37°C. 
Following incubation, colonies were picked from plates by scraping with sterile pipette tips and briefly 
immersing and pumping them in sterile LB broth laced with antibiotic concentrations equal to those of the 
corresponding plate. These broth solutions were incubated overnight at 37°C with shaking. Broth volumes 
of 50 mL were inoculated in order to maximize miniprep yields. 
 
Blue/White Screening 
 Blue/white screening was used to select colonies for the pCR 2.1 TOPO plasmids containing the 
two bsNOS fragments. Plates for this selection were poured identically to 100 µg/mL ampicillin plates 
with the exception that following sterilization 0.05% 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
(x-gal) and 0.005% Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added. Colonies growing with a 
blue coloration were expected to have taken in a plasmid without an insert and were not selected for 
further study. Selected colonies were then amplified in LB broth containing 100 µg/mL ampicillin and 
kanamycin and incubated at 37°C overnight. 
  
Plasmid Isolation 
 Plasmids were isolated using E. Z. N. A. Plasmid Mini Kit I (D6942-02, 200 preps) according to 
the manufacturer’s standard protocol, including two washes with DNA wash buffer. Stock culture 
volumes processed were increased to between 25 and 50 mL each (as opposed to the kit’s recommended 
1-5 mL) to increase yield at the expense of efficiency; doing so showed total plasmid yields to increase up 
to 20 fold for some plasmids. Additionally, once plasmid samples were loaded onto the microfuge 
columns they were allowed to sit 5 minutes prior to centrifugation. 
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Separation of Plasmid Fragments 
 Electrophoresis was performed on 100mL, 1% agarose gels containing 1.5 µM ethidium bromide. 
A stock solution of 50X TAE buffer (2 M Tris, 1 M acetic acid, 0.05 M EDTA, pH 8.0) was diluted to 
1X. Agar-agar was added (1 g) to 100 mL of 1X TAE and then dissolved using a microwave with 
periodic stirring. The clear solution was then allowed to cool to 65°C, and then 6 µL of 10 mg/mL 
ethidium bromide was added and mixed by stirring. The solution was allowed to cool to 55°C and then 
poured into a horizontal gel caster (BioRad Wide-Mini Sub Cell, No. 18S/7864) to solidify at room 
temperature for one hour. The gel was removed from the caster, placed into a horizontal gel box, and 
immersed in 1X TAE buffer. Samples without included loading dyes (ladders and PCR mixtures) were 
diluted to 80% in 5X loading dye (0.015% bromophenol blue, 40% [w/v] glycerol in deionized water) and 
added to gel wells by micropipette. Gels were then run at 80 V for up to 1.5 hours and quickly placed in a 
UV light box (UVP BioDoc-It Imaging System) for imaging. Gels from which samples were to be 
extracted had desired bands removed using a clean razor blade and then stored in a clear 1.5 mL 
microfuge tube for extraction. 
 
Restriction of Plasmid DNA 
 All digested samples were digested with one or more of the restriction enzymes XbaI, KpnI, or 
PstI. Mixtures consisted of 0.05 to 0.2 µg/µL of DNA or plasmid sample, depending on the purpose of the 
gel; higher DNA concentrations were used for digestions intended for excision and extraction of bands 
after electrophoresis, while mapping digestions and others in which no collection would be used were 
given lower concentrations of DNA. Additional components of digestion mixtures included 0.04 u/µL 
each of appropriate restriction enzymes, 0.1 mg/mL sterile bovine serum albumin (BSA), 1X multicore 
buffer solution, and deionized water. Digestion mixtures were incubated at 37°C for between 1 and 4 
hours, and were immediately mixed with loading dye and resolved through electrophoresis. Gels were 
imaged using a UV light box, and those with bands intended for extraction were excised. 
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DNA and Plasmid Ligations 
 Ligations were performed using vector/insert ratios specific to each step, which were determined 
by trial and error. DNA fragment solutions were combined and mixed by gentle tapping, and were heated 
to 50°C on a heat block for 5 minutes and then removed from heat and incubated on ice for 20 minutes to 
allow digested ends to combine. Next, 0.3 u/µL DNA ligase, 1X ligase buffer, and deionized water were 
added to volume, and the solution was left at room temperature for 1 hour and then incubated for between 
24 and 72 hours at 4°C. Prior to transformation, ligase was deactivated by heating ligation samples to 
70°C for 5 minutes. 
 
Purification of DNA Fragments from Agarose Gels 
 Excised gel bands were extracted using the QIAquick Gel Extraction Kit (Quiagen, Cat. # 28704) 
with a few modifications to the kits standard protocol. Gel fractions were massed and then dissolved in 
QG buffer at volumes of 2 µL/mg of gel (as opposed to the 3 µL/mg in the kit protocol), then incubated at 
50°C for 10 minutes with periodic vortexing. Next, isopropanol was added at 1/3 the added volume of QG 
buffer and mixed by inversion. Samples were then transferred into microfuge columns and allowed to sit 
for five minutes before being centrifuged, washed, and eluted according to the official protocol. 
 
Polymerase Chain Reaction 
 The sequence of the gene coding for Bacillus subtilis’ NOS enzyme was obtained from the 
National Center for Biotechnology Information (NCBI) website (26) and was divided roughly in half: the 
first 500 bp were chosen as the 5’ end of the gene, and the remaining 562 bp were chosen as the 3’ end. 
Primers were chosen to compliment the first ~35 base pairs of each half in both directions (5’ to 3’ and 3’ 
to 5’) as well as desired restriction sites and are identified as 5F (5’ Forward; sequence 
gggggggtaccatggaagaaaaagaaatactctgga), 5R (5’ Reverse; sequence 
ggggtctagaaaatccgttcgctctccgcgccagc), 3F (3’ Forward; sequence ggggtctagatgacctgctgccgctcatttttcgc), 
and 3R (3’ Reverse; sequence ggggctgcagttactcataaggcttatcttgataa). Primer 5F complimented the 
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sequence for a KpnI restriction site from the 5’ end of the bsNOS gene, and the 3R primer complimented 
the sequence for a PstI restriction site from the 3’ end. Both the 5R and 3F primers complimented the 
sequence for an XbaI restriction site from the 3’ and 5’ ends of their respective halves. These four primer 
sequences were purchased from Eurofins MWG Operon and were mixed with deionized water to give a 
100 µM solution of each, which were divided into 20 µL aliquots and stored at -20°C. 
 The PCR solution was mixed to contain 50% by volume of the GoTaq Green Mastermix 
polymerase solution (Promega Cat. # M7122), 42 ng of the isolated B.sub 168 DNA, and 10 µM 
concentrations of each desired primer. The mixture was then diluted to volume with deionized water and 
placed in a thermocycler. The thermocycler program was set for an initial temperature of 94°C for two 
minutes, followed by 30 cycles of 94°C for 30 seconds, 58°C for 30 seconds, and 72°C for 1 minute, 
before remaining at the annealing temperature of 72°C for 7 minutes and then being cooled to 4°C until 
removal. PCR samples were then stored at -20°C.  
 
Quantification of DNA Samples 
 Measurements of isolated DNA or plasmid sample concentrations were performed using 1µL of 
the measured sample on an ND-1000 spectrophotometer (nanodrop). After initialization with water 
appropriate solvents were used to zero the device; for plasmid samples isolated using the E.Z.N.A 
miniprep kit, 1 µL of the kit’s elution buffer was used. For plasmid or DNA samples extracted from an 
electrophoresis gel using the QIAQuick gel extraction kit, 1 µL of the kit’s elution buffer was used. DNA 
concentrations were recorded as well the ratio of absorbance at 260nm and 280nm. Given the tendency of 
DNA to absorb at 260 and proteins to absorb at 280nm, a higher value for the ratio of absorbance at these 
two wavelengths (260/280) indicates a solution with fewer protein contaminants. Samples with 260/280 
ratios of 2.0 to 1.6 were considered clean enough for use; others were discarded. 
 
Bacterial gDNA Isolation by Isopropanol Precipitation 
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 Stock cultures of Bacillus subtilis were grown to OD(595nm) = 0.600 and centrifuged at 13,200 rpm 
for 2 minutes at room temperature to pellet the cells, and the supernatant broth was decanted using a 
micropipette and the tube drained. Pellets were resuspended in sterile Tris-EDTA buffer (TE; 10 mM 
Tris, 1 mM EDTA, pH brought to 8.0 using 1M HCl) with 0.6% by volume of sodium dodecyl sulfate 
(SDS) and 120 µg/mL proteinase K. The solution was mixed and allowed to incubate for 1 hour at 37°C. 
 Next, an equal volume of a 1:1 mixture of phenol and chloroform was added and inverted until 
phases were mixed, and the vial was centrifuged at 13,200 rpm for 2 minutes at room temperature and the 
top aqueous layer was transferred into a new container. An equal volume of 1:1 phenol-chloroform was 
added and again mixed via inversion until the phases had mixed, and the vial was again centrifuged. The 
aqueous  phase was transferred into a clean tube and 0.6 volumes of isopropanol was added and mixed by 
inversion until a DNA precipitate formed. The vial was centrifuged at 13,200 rpm to pellet the DNA 
precipitate and the supernatant was decanted. The DNA pellet was then washed with 70% ethanol, 
centrifuged to re-pellet the precipitate, decanted, and resuspended in sterile TE buffer (pH 8.0). DNA 
stocks were then stored at -20°C. 
 
Production of 5’ and 3’ bsNOS DNA Fragments 
 A starter culture of Bacillus subtilis was grown overnight and then the genome was isolated by 
isopropanol precipitation. Next, PCR was performed for both the 5’ and 3’ fragments of the bsNOS gene. 
For the 5’ sample, 5F and 5R primers were added. For the 3’ sample, 3F and 3R primers were added. The 
PCR mixture was then cleaned using electrophoresis on a 1% agarose gel with 100 bp and 1 kb ladders 
added as controls and imaged. Bands identified at 500 bp (5’ fragment) and 600 bp (3’ fragment) were 
excised and extracted. A diagram depicting the PCR primer setup and amplification products is shown in 
Figure 2.1. 
 Amplification and digestion of bsNOS DNA fragments was achieved using a pCR 2.1 TOPO 
plasmid kit, with 1:8 volumes each of plasmid, DNA, and salt solutions added and diluted with deionized 
water. These samples were incubated 30 minutes at room temperature and then transformed into DH5α 
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stocks and selected using 100µg/mL ampicillin and kanamycin blue/white plates. White colonies were 
amplified in 50 mL LB with 100 ng/µL ampicillin and kanamycin and incubated overnight at 37°C with 
vigorous shaking. Plasmids were isolated by miniprep and resulting plasmid concentrations were 
identified using nanodrop. Stocks of pCR TOPO plasmids with the 5’ or 3’ insert were kept for future 
transformations. 
 DNA inserts within 5’ TOPO plasmids were released by digestion using XbaI and KpnI digestive 
enzymes, while 3’ TOPO plasmids were digested with XbaI and PstI. The resulting digests were cleaned 
using electrophoresis and the resulting 500 and 600 bp bands (5’ and 3’ samples, respectively) were 
excised, extracted, and stored at -20°C. 
 
Production of p34S KAN Insert 
 The p34S plasmid coding for kanamycin resistance was received from Dr. Andre Hudson’s 
inventory stock. Cell culture shavings from this strain were introduced to a 50 mL volume of sterile LB 
broth using a pipette tip and incubated with shaking at 37°C overnight. Next, sterile streaking technique 
was used to plate the culture on an LB-agar plate with 50 µg/mL kanamycin sulfate, and this plate was 
incubated at 37°C overnight. After incubation, colonies were taken from the kanamycin plate using sterile 
technique and introduced to 15 mL solutions of sterile LB broth laced with 50 µg/mL kanamycin sulfate 
and incubated at 37°C with shaking overnight. The following day 14 mL of this culture was transferred to 
a 15 mL conical tube and centrifuged to pellet the cells. The broth was decanted and disposed of, 
plasmids were extracted from cell pellets using miniprep, and the resulting plasmid solution was stored at 
-20°C. 
 The p34S plasmid was amplified by transformation into DH5α, followed by selection on a 
100ng/µL kanamycin plate and amplification in 50 mL of 100ng/µL kanamycin LB broth. Plasmids were 
isolated using miniprep and stored at -20°C. 
 To extract the KAN resistance gene insert, the p34S plasmid was digested with XbaI for 2 hours 
and then run on a 1% agarose electrophoresis gel using 2 µg undigested p34S plasmid, along with 100 bp, 
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and 1 kbp VWR DNA ladders as controls. The gel was then imaged and the band corresponding to ~1 kbp 
fragment size was excised, extracted, and stored at -20°C. 
 
Production of pUC19 Vector Fragment 
 A solution of pUC19 plasmid received with DH5α stock cultures (Invitrogen, ~ 10 pg/µL) was 
used to transform a DH5α aliquot, and was selected on 100 ng/µL ampicillin plates. Amplification was 
done in 50 mL of LB with 100 ng/µL ampicillin. Plasmids were isolated using miniprep and stored at -
20°C. The pUC19 stock was then digested with KpnI + PstI for 2 hours at 37°C in a water bath and then 
run on a 1% agarose electrophoresis gel using 2 µg undigested pUC19 plasmid, 100 bp, and 1 kbp ladders 
as standards. The gel was then imaged and the ~2.7 kbp band was excised, extracted, and stored at -20°C. 
 
Production of pNOS20 Phase I Plasmid 
 The phase I plasmid, pNOS20, was created by ligating together the pUC19 vector fragment and 
the 5’ and 3’ bsNOS fragments in a 1:10:10 ratio, respectively (Dr. Andre Hudson). The ligation 
procedure was followed and the mixture incubated for 72 hours, deactivated, and then transformed into a 
DH5α aliquot and selected using 100 ng/µL AMP plates. Resulting colonies were amplified using 50 mL 
of LB broth with 100 ng/µL AMP and incubated overnight. Samples were then miniprepped, 
concentrations were measured by A260/A280 using a Nanodrop spectrophotometer, and the plasmid was 
map digested with KpnI + XbaI and PstI + XbaI to observe the presence of 5’, 3’, and pUC19 vector 
fragments. Plasmid stock was stored at -20°C. 
 
Production of pUC19∆bsNOS Phase II Plasmid 
 The phase II plasmid, pUC19∆bsNOS, was created by first linearizing pNOS20 with XbaI and 
then ligating it together with the digested p34S KAN insert at a 1:10 ratio, respectively. The ligation 
procedure was followed and incubated at 4°C for 24 hours, deactivated, and then transformed into a 
DH5α aliquot and selected for using 100 ng/µL AMP + KAN plates. Resulting colonies were amplified 
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using 50 mL LB broth with 100 ng/µL AMP + KAN incubated overnight. Plasmids were extracted using 
a miniprep kit and concentrations were measured by UV absorbance on a Nanodrop spectrophotometer, 
and the plasmid was map digested with PstI + KpnI to observe the presence of 5’, 3’, KAN insert, and 
pUC19 vector fragments. Plasmid stock was stored at -20°C.  
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Figure 2.1. Schematic of PCR Amplification of bsNOS Gene from genomic DNA to give 5' and 3' 
half-fragments of the bsNOS gene with respective restriction sites. Primers are shown as red arrows, 
bsNOS-coding DNA is shown in blue, restriction-site DNA is yellow, and non-bsNOS coding DNA is 
shown in gray. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Schematic of pUC19ΔbsNOS
 
 
  
 Production from starting components to insert sequence.
23 
 
24 
 
Chapter 3: Results 
 Following the isolation of Bacillus subtilis 168's genomic DNA, ~15 ng of DNA was loaded into 
PCR mixtures for 5’ (500 bp) and 3' (600 bp) fragments.  The gene fragments were amplified with custom 
primers and separated using gel electrophoresis, and the resulting gel is shown in Figure 3.1. All six 
bands were excised and extracted separately to give different undigested 5' and 3' DNA samples. The 
sizes of these bands with respect to each other and to the DNA ladders suggest that the amplification was 
successful, though the different relative intensities of these bands may indicate slight differences in the 
reaction’s efficiency or more likely may simply be the result of shorter chain lengths containing fewer 
numbers of ethidium bromide-binding nucleotides. 
 After extracting these bands, both 5' and 3' fragment stocks were ligated into pCR TOPO 2.1 and 
the resulting plasmid was used to transform cultures of Escheria coli strain DH5α, selected for using 
ampicillin and kanamycin at 50 µg/mL. After amplifying and miniprepping the colonies, 12 µg of the 5’ 
and 3’ TOPO plasmids were digested with KpnI and PstI, respectively, along with XbaI in 50 µL 
mixtures. The digestion mix was then run through an electrophoresis gel, pictured in Figure 3.2, and the 
bands corresponding to the 5' and 3' inserts (500 and 600 bp, respectively) were excised. Fragments cut 
from pCR TOPO plasmids are considered fully digested as removal from the plasmid necessitates 
digestion, and so the 5' and 3' bsNOS fragments were now extracted and stored prior to ligation. 
 The vector plasmid pUC19 was now amplified through DH5α and selected for using 50 µg/mL 
ampicillin plates. After growth and isolation, 200 ng of each were added to a 20 µL digestion mixture 
containing restriction enzymes KpnI and PstI. The mixtures were then incubated and run through an 
electrophoresis gel, pictured in Figure 3.3. Some additional fragments were seen in undigested plasmid 
samples, though these were likely a consequence of supercoiling or linearization due to random 
degradation in the undigested plasmids. Excised bands from pUC19 and p34S plasmids were extracted to 
give solutions of digested pUC19 and KAN fragments, respectively. 
 A ligation mixture was produced containing a 1:10 ratio of digested pUC19 vector to digested 5' 
and 3' inserts and incubated for 48 hours at 4°C. Following ligation the mixture was deactivated by 
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incubation at 70°C for five minutes and then was used to transform samples of DH5α. These samples 
were plated on agar with 50 µg/mL ampicillin and then nine colonies were selected for amplification, 
after which plasmid content was isolated via miniprep as pNOS20 candidate samples (A through I). 
 To test for the desired inserts a mapping digest was performed in which roughly 0.1 µg of each 
plasmid sample was added to a 10 µL digestion mixture containing the restriction enzymes XbaI and KpnI 
in order to cut out the 5' fragment from each plasmid. After incubation these digestion mixtures were 
loaded into a 30-lane agarose gel to check for the desired band patterns. The desired plasmid should give 
a 500 bp fragment under these digestion conditions, and all but one sample (sample D) showed bands of 
this size, as seen in Figure 3.4. All samples with the exception of D were then tested for a 3' fragment 
insert in the same fashion; roughly 0.1 µg of each was digested in a 10 µL digestion mixture containing 
XbaI and PstI restriction enzymes. The correct plasmid ligation should give a 600 bp fragment under 
these conditions. An agarose gel was poured and the samples were run through it to check for the desired 
fragment; the resulting gel is shown in Figure 3.5. All samples were shown to have the 3' insert as well, 
and were thus confirmed to be the desired pNOS20 plasmid product. 
 Three of the confirmed pNOS20 samples (B, C, and F) were selected to be linearized with XbaI. 
Three 20 µL digestion mixtures were prepared containing 4 µg of each respective plasmid sample and the 
XbaI restriction enzyme. An additional digest was performed using XbaI on a sample containing p34S 
plasmid in order to provide an additional control sample as well as a fresh sample of the digested KAN 
fragment for extraction. After incubation the samples were run through an agarose gel with 1kbp and 
100bp VWR ladders as controls. This gel is shown in Figure 3.6. The digested bands from each sample as 
well as the 1.1 kbp p34S digest band were excised and extracted to give solutions of linearized pNOS20 
as well as the digested KAN gene, respectively. 
 Following excision a ligation mixture was produced containing a ratio of 1:10 pNOS20 to KAN 
insert, with a total of approximately 100 ng of DNA in 25 µL ligation mixtures. The ligation mixture was 
incubated 24 hours and then deactivated before being used to transform samples of DH5α. After rescue, 
transformed samples were grown on plates laced with 50 µg/mL kanamycin and ampicillin and four 
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colonies were selected for amplification (A, B, C, and D). After amplification, plasmids were extracted 
via miniprep to yield solutions of pUC19∆bsNOS candidates. These plasmid solutions were then 
digestion mapped to test for the presence of 5', 3', and KAN inserts. To do this, 20µL digestion mixtures 
were made containing ~0.2 µg of plasmid along with PstI and KpnI restriction enzymes. Given the 
presence of all three restriction sites at the ends of the KAN insert, this mixture would be expected to 
liberate all four fragments from the plasmid, yielding a fragmentation pattern with bands at 500 bp, 600 
bp, 1.1 kbp, and ~2.7 kbp. Following incubation the digestion mixtures were run through a 15-well 
agarose gel alongside undigested samples and a 1 kbp and ladder as controls. This gel is shown in Figure 
3.7. Based on the resulting digestion patterns, all five selected colonies yielded pUC19∆bsNOS plasmids. 
 With digestion mapping results which suggested that the goal of generating pUC19∆bsNOS had 
been accomplished, the final confirmation needed was to sequence the generated plasmid's insert through 
the University of Rochester's sequencing lab (27). While the total pUC19∆bsNOS plasmid was available, 
the pNOS20 plasmid was submitted for sequencing as the KAN gene sequence is already known and 
would have doubled the required sequence to be amplified. As such, samples from pNOS20 candidate F 
were produced and submitted to the University of Rochester to be sequenced. When run through the 
National Center for Biotechnology Information's online BLAST, the sequence returned appears identical 
to that of bsNOS: among the four samples submitted, total sequence similarity and maximum alignment 
scores average out to be 97.8% and 1810, respectively. The minimum sequence similarity seen from any 
of the samples was 97%, and the lowest maximum alignment score was 1753. Overall, it appears 
definitive that the pNOS20 sample selected was correctly identified, and from this it can be extrapolated 
that its ligation with digested KAN should have formed the pUC19∆bsNOS plasmid, again confirming 
mapping digest data (11). An example of the sequence alignment data given by BLAST search is shown 
in Figure 3.8. 
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Figure 3.1. PCR-Amplified bsNOS Fragment Gel, showing 5' and 3' fragments resolved on an 
electrophoresis gel. The 5' fragments were all excised to give 5' fragment samples, and the 3' fragment 
bands were all excised to give 3' fragment samples. Lanes 1 and 15 contain a mixture of VWR 1kb and 
100 bp ladders; lanes 3, 5, and 7contain 5' PCR mixtures, and lanes 9, 11, and 13 contain 3' PCR 
mixtures. 
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Figure 3.2. 5' and 3' TOPO Plasmid Digests, before and after their digestion. The 500 bp fragment 
from the 5' TOPO digestion was excised for extraction to give the digested 5' fragment solution. The 600 
bp fragment from the 3' TOPO digestion was excised for extraction to give the digested 3' fragment 
solution. Lanes 1 and 2 contain VWR 1kbp and 100 bp ladders, respectively. Lane 3 contains undigested 
5' pCR TOPO plasmid, and lane 4 contains digested 5' pCR TOPO plasmid. Lane 5 contains undigested 3' 
pCR TOPO plasmid, and lane 6 contains digested 3' pCR TOPO plasmid. 
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Figure 3.3. Digestion of pUC19 and p34S plasmids. For pUC19 the second fragment removed 
through digestion is too small (<100 bp) to be identified on a 1% gel with given concentrations of 
ethidium bromide; thus the 2.6 kbp band was the only one observed after digestion and was subsequently 
excised for extraction. The p34S digestion yielded two fragments: one at ~1 kbp and another at ~2.5 kbp. 
The 1 kbp fragment correlated with the desired KAN resistance gene, and so was excised for extraction. 
Undigested plasmid sizes (lanes 3 and 5) were measured from the faint lines seen above the larger spots 
as the larger spots likely represent plasmid sizes after supercoiling and therefore do not accurately 
represent the undigested plasmid's size. Lanes 1 and 2 contain VWR 1kbp and 100 bp ladders, 
respectively. Lanes 3 and 5 contain undigested pUC19 and p34S plasmids, respectively, while lanes 4 and 
6 contain digested pUC19 and p34S, respectively. 
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Figure 3.4. 5' Digestion Mapping  Gel of pNOS20 ligation samples to test samples A through I for the 
presence of the 5' bsNOS fragment insert. Samples both digested and undigested were run, with 1 kbp and 
100 bp ladders for control. All but sample D exhibited the desired 500 bp fragment. Lanes 1 and 22 
contain a VWR 1 kbp ladder, and lanes 2 and 21 contain a VWR 100 bp ladder. Odd numbered lanes 
from 3 to 19 contain undigested samples A through I (left to right), and even numbered lanes from 4 to 20 
contain digested samples A through I (left to right). 
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Figure 3.5. 3' Digestion Mapping  Gel of pNOS20. Testing of samples A through I (sans D) for the 
presence of the 3' bsNOS fragment insert. All samples exhibited the desired 600 bp fragment. Lanes 1 and 
2 contain VWR 1 kbp and 100 bp ladders for control. Lanes 3 through 10 contain digested samples A 
through I (left to right, sample D not processed). 
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Figure 3.6. pNOS20 Linearization Gel. Ligation samples B, C, and F linearized with XbaI. Undigested 
plasmids traveled slightly further due to supercoiling and so comparisons between digested and 
undigested plasmid confirm that digestion did occur in each case. Bands of linearized samples were 
excised for extraction. Plasmid p34S was also digested with XbaI and run alongside an undigested 
control; the ~1 kbp fragment band of this digest was extracted as a source of fresh digested KAN gene 
sequence. Lanes 1 and 2 contain VWR 1 kbp and 100 bp ladders, respectively. Lanes 3, 5, and 7 contain 
undigested plasmid samples B, C, and F, respectively, and lanes 4, 6, and 8 contain their digested 
counterparts, respectively. Lane 9 contains undigested p34S (after supercoiling), and lane 10 contains 
digested p34S. 
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Figure 3.7. Digestion Mapping Gel of pUC19ΔbsNOS Candidates. Samples A-D were digested with 
PstI and KpnI, and were run alongside undigested samples. All four samples appear to include all four 
component fragments, suggesting that the pUC19∆bsNOS plasmid has been successfully constructed in 
each case. Lane 1 contains a VWR 1 kbp ladder. Lanes 2, 4, 6, and 8 contain undigested samples A 
through D (after supercoiling), and  lanes 3, 5, 7, and 9 contain samples A through D after digestion. 
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Figure 3.8. Sequence Alignment of  the pNOS20 Insert as compared by NCBI BLAST search  to the 
wild-type bsNOS gene. The upper line of each row represents the plasmid sequence submitted, and the 
lower sequence is taken from the bsNOS genome. Vertical lines represent identical bases, while missing 
lines represent mismatches. (11). 
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Chapter 4: Discussion  
 Based on the sequence data returned by the University of Rochester and the mapping digests 
performed, it can be concluded that the pUC19∆bsNOS plasmid has been successfully constructed and 
should be easily amplified and/or used for transformation of Bacillus subtilis. The use of pUC19 as a 
vector makes amplification easy through transformation and selection of DH5α, though given that PCR is 
to be used to generate the desired fragments from the pUC19∆bsNOS only very small concentrations of 
this plasmid should be needed. 
 The next step in this method will be the transformation of wild-type Bacillus subtilis 168 with the 
insert. Ideally, treatments should be possible simply by electroporating the entire pUC19∆bsNOS plasmid 
into competent B.sub stocks, but to date this method has not worked. It is possible that even after 
unraveling the extra 2.7 kbp of non-insert plasmid regions are making encounters between the insert 
strand and its compliment difficult; in any case it was decided that the insert needed to be removed from 
the plasmid before the transformation could work efficiently. 
 Removal of the insert sequence (roughly 2.1 kbp in length) was originally going to be 
accomplished using the KpnI and PstI restriction sites, but the presence of both sites on either end of the 
KAN gene of the p34S plasmid make it impossible to sever the insert as a whole using only the restriction 
enzymes in our stock. It could be possible to remove this strand using different restriction enzymes, but 
prior to this it was decided that using PCR to amplify our desired strand would be most efficient. First, it 
should allow the sequence to be generated in its entirety without any additional non-coding regions of the 
plasmid being brought along (as would be necessary if new restriction sites down-stream of the insert 
were to be targeted). Second, the use of PCR means that very low concentrations of pUC19∆bsNOS 
plasmid would be needed for a transformation procedure, and that if needed a much higher number of 
insert copies could be generated than may be possible using digested and cleaned plasmid minipreps. 
 PCR amplification of the insert from the pUC19∆bsNOS plasmid has already been performed 
and indeed has appeared successful. Bacillus subtilis colonies were seen on 40 µg/mL kanamycin plates, 
and to date over a dozen colonies have been selected, grown, and their DNA isolated by isopropyl 
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precipitation. Once this DNA is purified it should be possible to use PCR to amplify the insert from the 
genomic DNA; a successful double-recombination should give only one band at approximately 2.1 kbp, 
while a single recombination should show two bands: one at 2.1 kbp and another at 1 kbp. Unfortunately, 
complications have arisen in the PCR process. For reasons yet unknown, amplification of the bsNOS site 
has proven difficult. 
 While our described methods were (and still are) fully capable of amplifying the 5' and 3' halves 
of the gene independently, the 1 kbp wild type sequence has been problematic, giving very low yields 
based on band luminosity and suggesting that some variable in amplification efficiency has yet to be 
identified. As of this writing all colonies isolated have been tested, but only one or two (wild-type or 
treated) have shown definitive 1 kbp bands (indicating at best a single recombination product),  
and none have shown the 2.1 kbp band associated with a complete insert. Given that all colonies have 
been selected from kanamycin plates and that a full plasmid was not inserted it can be assumed that the 
KAN gene has inserted into the genome at some locus, and it is statistically unlikely that this occurred at a 
random region of the genome (although this possibility is not being ignored). Further, all colonies isolated 
give strong 500 or 600 bp bands when the 5' or 3' halves are amplified, indicating that all primers are 
finding targets and that the colonies isolated are all in fact Bacillus subtilis. If a complication in the PCR 
procedure is preventing the 1 kbp strand from being amplified, it is very likely that the same complication 
is making the 2.1 kbp insert even more difficult. Consequently, the lack of a 2.1 kbp band cannot yet be 
attributed to a lack of an insert, and so these issues with PCR products must be overcome before 
definitive testing of the potential knockout mutants can begin. Variables to be changed so far include 
timing programs for the thermocycler used in the PCR process as well as changes in DNA or primer 
concentrations. 
 While definitive PCR data is still lacking, the colonies themselves do appear promising. Wild-
type Bacillus subtilis does not grow on kanamycin plates, and yet the treated colonies are showing up as 
small, interspersed "pin-prick" colonies, a pattern typical of such transformation procedures. Additionally, 
wild-type Bacillus subtilis, even when selected from culture plates, grows rapidly and with high viability; 
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colonies selected can normally be incubated in LB broth overnight and consistently give turbid cultures. 
Colonies selected from the kanamycin plates, however, grow very slowly, and with a roughly 70% 
success rate. Incubation of selected colonies in even 10 ng/µL kanamycin (25% of the concentration used 
in the selection plate) took between 48 and 72 hours to reach even low turbidity, and 30% of colonies 
selected apparently fail to take hold. This low viability is likely due in part to the presence of kanamycin, 
but it is also consistent with the findings of other works in which bsNOS knockouts showed lower cell 
viability in the presence of antibiotics (17). 
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Chapter 5: Conclusions 
 Current work has strongly suggested that nitric oxide is manufactured in Bacillus subtilis at levels 
far below those necessary for recently observed oxidative stress mechanisms even at times of non-
stressed, logarithmic growth. This may indicate a native pathway in which NO is a key signal, and to date 
work is underway to identify just what this signal promotes. A simple means of identification is to inhibit 
production of this molecule and observe consequent changes proteomically, and while previous work 
allowed native bsNOS to be inhibited chemically it is also necessary to account for the presence of the 
added inhibitory chemical species. This will be accomplished using a genetic knockout of bsNOS. An 
antibiotic resistance gene inserted into the center of the bsNOS gene should inhibit the bacterium from 
producing native NO, and thus any signals carried by this molecule will be silenced. With the 
pUC19∆bsNOS plasmid complete, the only steps that remain in generating this knockout species include 
selecting a successful knockout colony and confirming its status as a complete knockout. 
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